Revenue

3 Months Ended

Dec. 31, 2021

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.

	Three Months Ended December 31,
(In thousands)	2021		2020
Medical Device
Product sales	$	6,788	$	4,561
Royalties		6,886		7,909
License fees		1,213		1,425
Research, development and other		2,021		2,301
Medical Device Revenue		16,908		16,196
In Vitro Diagnostics
Product sales		5,556		5,541
Research, development and other		539		560
In Vitro Diagnostics Revenue		6,095		6,101
Total Revenue	$	23,003	$	22,297

Contract assets totaled $6.7 million and $7.1 million as of December 31, 2021 and September 30, 2021, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected, at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangement.